Partnership collaboration: the SynBio3 technology platform at the heart of innovation
The SynBio3 "polymer platform" technology platform, in collaboration with the IBMM's "Polymers for Health and Biomaterials" department, the Montpellier Proteome Cluster, and MedinCell, have joined forces on the BIOPOLTRACE project.
Winner of the 2020 Regional Research Innovation Platforms (PRRI) call for proposals, the BIOPOLTRACE project aims to develop new methods for monitoring the in vivo degradation of polymers used in the medical and pharmaceutical fields.As part of the regulatory requirements associated with the marketing of an implantable medical device or injectable drug, the evaluation of the degradation of the materials used, the identification of degradation products, and the question of the fate of these degradation products are central to obtaining CE marking or marketing authorization.
To date, polymers such as polylactic acid (PLA) and polyethylene glycol (PEG) contained in medical devices and drugs are subject to these requirements. However, current methods for monitoring polymer degradation using radioactive or fluorescent probe labeling techniques are limited and have many drawbacks.
BIOPOLTRACE aims to overcome these limitations by enabling the in vivo monitoring of the degradation of PLA-PEG copolymers using analytical methods such as Maldi-Tof mass spectrometry and liquid chromatography coupled with mass spectrometry (LCMS, LC 2D/MS, SEC, etc.).
In addition, carbon-13 isotopic labeling of the species under study will also be used, notably to improve the sensitivity of analytical techniques.
Contacts: Vincent Darcos – Benjamin Nottelet